11 December 2025
EMA/121136/2025
European Medicines Agency

CTIS Simplification Task Force

Topics for analysis

Topic	Status of analysis	Recommendation
CTIS role matrix	Analysis complete.	The Task Force has recommended a revised roles matrix that reduces complexity by reducing the number of user roles.
Safety	Analysis complete.	The Task force has recommended the creation of a new safety module, with the aim to simplify the overall business rules for the Annual Safety Report (ASR) while enabling the selection of the safety assessing Member State (saMS) in CTIS. The release of the new safety module is planned for Q2 2026.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union

© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.

Topic	Status of analysis	Recommendation
CTIS timetable visualisation	Analysis complete.	The Task Force has recommended to keep the timetable in CTIS and increase awareness on the functions of this feature.
Investigational Medicinal Product Dossier – Quality (IMPD-Q) only applications	Analysis complete.	The Task Force has recommended to keep the current process while closely monitoring whether there is a need to implement an alternative solution in the future.
User Management	Analysis complete.	The Task Force has recommended to implement key improvements that will provide immediate benefits to administrators, with the aim to make the user administration more efficient and user friendly.
Ad-hoc assessment	Analysis complete.	The Task Force has recommended to keep the current process with potential implementation of some improvements based on priorities.
Lock mechanism	Analysis complete.	The Task Force has recommended reducing the number of locks only in the Request for Information (RFI) sections to streamline the RFI response process for sponsors.
Clinical Trial Application (CTA) Workflow	Analysis ongoing, with the aim to introduce more flexibility for users in the submission of clinical trial applications. This topic includes the following sub-topics: a) Application submission rules b) Notices and alerts c) Workflow automatic business rules d) Tasks	a) The Task Force has recommended increasing flexibility in the rules for submission of clinical trial applications, prioritising Substantial Modifications/Non-Substantial Modifications Part II and Additional Member State Concern applications. b) The Task Force has recommended deleting notices and alerts 90 days after receipt (implemented Q3 2025), reducing the number of Notices and Alerts, and

Topic	Status of analysis	Recommendation
	e) Requests for Information and considerations f) Cloning functionality	introducing email notifications in early 2026, among other recommendations. c) The Task Force has recommended keeping the workflow automatic business rules in the system as-is. d) The Task Force has recommended a revision of the RMS selection process. e) The Task Force has recommended key improvements in the Request for Information and Considerations tab to enhance user experience. The Task Force has also agreed to explore the use of a collaborative tool in the authority workspace, and analyse the need for a communication tool in CTIS (see topic below). f) Recommendation pending
Member State Application Programming Interface (API)	Analysis ongoing.	N/A
Download management	Analysis complete.	The Task Force has recommended to implement key improvements in the "All documents" table and "Download" feature to improve the user experience and increase overall productivity.
Collaboration tool	Analysis ongoing.	N/A
Review of structured data	To be analysed in 2026.	N/A